Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 [Yahoo! Finance]
Inventiva S.A. - American Depository Shares (IVA)
Company Research
Source: Yahoo! Finance
Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million , and long-term deposit at €9.0 million as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 Receipt on January 18, 2024 of the second tranche of €25 million under the EIB loan agreement Estimated cash runway until the beginning of the third quarter of 2024 Patients currently enrolled in the Phase III NATiV3 trial are continuing treatment as Inventiva has voluntarily paused screening and randomization of new patients to implement additional screening eligibility criteria recommended by the independent Data Monitoring Committee following review of a reported treatment–related Suspected Unexpected Serious Adverse Reaction (SUSAR) of elevated aminotransferases in a patient enrolled in the trial This SUSAR is the first reported in all clinical trials with lanifibranor. Prior to this voluntary pause, Inventiva was on track to complet
Show less
Read more
Impact Snapshot
Event Time:
IVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVA alerts
High impacting Inventiva S.A. - American Depository Shares news events
Weekly update
A roundup of the hottest topics
IVA
News
- Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2024 Featuring 100+ Companies and 110+ Pipeline Drugs Including Lanifibranor (Inventiva Pharma), MSDC-0602K (Cirius Therapeutics), TERN-501 (Terns Pharma) [Yahoo! Finance]Yahoo! Finance
- Inventiva S.A. (NASDAQ: IVA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F [Yahoo! Finance]Yahoo! Finance
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FGlobeNewswire
- Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
IVA
Sec Filings
- 5/3/24 - Form SC
- 4/3/24 - Form 20-F
- 3/27/24 - Form 6-K
- IVA's page on the SEC website